Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00896025 · ClinicalTrials.gov registry record · Phase 4
Study of N-Acetylcysteine in Acute Liver Failure (ALF)
A Phase 4 study, sponsored by University of Texas Southwestern Medical Center.
- Terminated
- Registry status
- Phase 4
- Development phase
- 255
- Enrollment target
NCT00896025 is a Phase 4 study that was terminated before completion, run by University of Texas Southwestern Medical Center. The registered enrollment target is 255 participants.
The verdict
NCT00896025, a Phase 4 study, was terminated before completion, sponsored by University of Texas Southwestern Medical Center.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 255 participants
- Enrollment target
Study Summary
This proposed study is a multi-center open label study to determine if N-acetylcysteine has any survival benefits in patients with acute liver failure.
Interventions
- DRUG N-acetylcysteine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 255 participants |
| Start Date | 2008-12 |
| Est. Completion | 2016-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00896025
The ClinicalTrials.gov registry entry for NCT00896025 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 255 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which N-acetylcysteine is the first listed.
NCT00896025 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00896025 about?
NCT00896025 is a clinical study titled "Study of N-Acetylcysteine in Acute Liver Failure (ALF)". This proposed study is a multi-center open label study to determine if N-acetylcysteine has any survival benefits in patients with acute liver failure.
What is the current status of trial NCT00896025?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 255 participants. The study started on 2008-12. Estimated completion is 2016-03.
What interventions are being tested in trial NCT00896025?
The interventions under investigation include: N-acetylcysteine (DRUG).
Who is sponsoring clinical trial NCT00896025?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.